DFTX

Definium Therapeutics, Inc.

DFTX · CIK 0001813814 · Annual (10-K) · Last 5 years

Financial Trends

Revenue
20212025
Net Income−$184M
20212025
Operating CF−$132M
20212025
Free Cash Flow
20212025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Revenue—————
Cost of Revenue—————
Gross Profit—————
R&D Expense$0.1B$0.1B$0.1B$0.0B$0.0B
SG&A Expense—————
Operating Income$-0.2B$-0.1B$-0.1B$-0.1B$-0.1B
Net Income$-0.2B$-0.1B$-0.1B$-0.1B$-0.1B
EPS (Basic)$-2.06$-1.54$-2.44$-1.84—
EPS (Diluted)$-2.06$-1.54$-2.44$-1.84—

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Total Assets$0.4B$0.3B$0.1B$0.2B$0.2B
Current Assets$0.4B$0.3B$0.1B$0.1B$0.1B
Cash & Equivalents$0.3B$0.3B$0.1B$0.1B$0.1B
Total Liabilities$0.1B$0.1B$0.0B$0.0B$0.0B
Current Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.3B$0.2B$0.1B$0.2B$0.2B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
Investing Cash Flow$-0.2B——$-0.0B$-0.0B
Capital Expenditures—————
Financing Cash Flow$0.3B$0.3B$0.0B$0.1B$0.1B
← Companies